Keytruda access in Egypt: the EDA named-patient pathway
How Egypt patients legally obtain Keytruda (pembrolizumab) when the locally registered indication, presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Egypt access Keytruda (pembrolizumab) for multiple FDA-labelled oncology indications through the EDA personal-use import pathway, a federal mechanism that allows an Egyptian-licensed physician to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
How Keytruda reaches patients in Egypt
Keytruda (pembrolizumab, anti-PD-1 humanised IgG4 monoclonal antibody, FDA-approved 2014 with extensive subsequent label expansions across more than 18 cancer indications; marketed by Merck and Co / MSD globally) is partially registered with the EDA through MSD Egypt for selected indications; check current status at eservices.edaegypt.gov.eg/EDASearch/SearchRegDrugs. Where the prescribed indication, dosing schedule, or combination regimen is not locally registered or stocked (newer indications often reach EDA registration 12 to 36 months after FDA approval), Egyptian patients access Keytruda via Personal Importation of Unregistered Medicines, the EDA Central Administration for Pharmaceutical Affairs permit, under Pharmacy Practice Law No. 127 of 1955 read with Health Minister Decree No. 296 of 2009 and Law No. 151 of 2019. The Keytruda-specific clinical justification must document: tumour type, stage, prior therapy lines where applicable, biomarker status where indication-relevant (PD-L1 CPS or TPS, MSI-H or dMMR status, TMB high status, HER2 status for selected GI indications), and the intended combination regimen per the FDA label. The supporting medical report is stamped by the treating Egyptian-licensed oncologist. Cold-chain handling (2 to 8 degrees Celsius) documentation is included. EDA processing is 1 to 3 weeks; biologics with cold-chain handling may run toward the longer end of the range.
Where Keytruda is administered in Egypt
Keytruda is an IV outpatient infusion given every 3 or 6 weeks across solid-tumour and haematologic indications; the dispensing setting is infusion-capable medical oncology day-care. Egyptian tertiary oncology nodes administering pembrolizumab include the National Cancer Institute (NCI) Cairo University Department of Medical Oncology in Cairo at nci.cu.edu.eg, Egypt's flagship public cancer centre with the largest annual oncology case load; Cairo University Hospitals (Kasr Al-Ainy) Department of Clinical Oncology and Nuclear Medicine; Ain Shams University Hospitals Department of Clinical Oncology and Nuclear Medicine; Alexandria University Hospitals Faculty of Medicine Department of Clinical Oncology (Shatby and Smouha campuses); Mansoura University Hospitals Oncology Center (OCMU) Department of Medical Oncology; Baheya Foundation for Early Detection and Treatment of Breast Cancer in Cairo at baheya.org for early-line breast cancer indications; and the Cleopatra Hospitals Group oncology services in Cairo for private-tertiary case load. NCI Cairo, Cairo University Kasr Al-Ainy, and Alexandria University Hospitals are the most-frequent dispensing nodes; they publish departmental leadership and run structured tumour boards for immune-checkpoint inhibitor candidate selection.
What Keytruda costs in Egypt
The US reference WAC for Keytruda is approximately USD 11,000 to USD 11,500 per 100 mg vial; the standard adult dose (200 mg every 3 weeks or 400 mg every 6 weeks) drives a US WAC in the range of USD 22,000 to USD 23,000 per 3-week cycle and approximately USD 190,000 to USD 200,000 annually at maintenance per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. MSD Egypt distributes pembrolizumab for the EDA-registered indications; selected Egyptian oncology-procurement reports have placed locally-procured EGP prices for Keytruda 100 mg in the range of EGP 90,000 to EGP 120,000 per vial historically, though EGP volatility (multiple devaluations 2022 to 2024) and the locally-stocked-versus-named-patient-import gap makes a stable single-figure citation unreliable; do not extrapolate. Price snapshot: 2026-05-31. The EGP/USD spot rate from the Central Bank of Egypt on the date of any firm quote should be footnoted. Cost layers: cold-chain international logistics (mid four-figure USD for refrigerated lanes), EDA permit and customs (nominal), the dispensing hospital's infusion-administration fees, and Reserve Meds concierge fee itemised separately.
Funding and access barriers for Keytruda in Egypt
Pembrolizumab is the highest-volume immune-checkpoint inhibitor globally and the most-prescribed oncology biologic in Egyptian tertiary practice for FDA-label indications. Public-sector funding: UHIA at uhia.gov.eg in implementation governorates includes oncology services; UPA-co-developed HTA adjudication on Keytruda for specific indications has been formalised through MSD Egypt's HTA submissions for selected EDA-registered indications. UPA centralised procurement at upa.gov.eg is the single-window for public-sector purchasing including pembrolizumab for the registered indications. Treatment at State Expense (Nafaqat Ala Al-Dawla) covers selected high-cost oncology drugs case-by-case for Egyptian nationals lacking means; pembrolizumab is on the case-by-case-eligible list for selected indications subject to committee approval. Major private insurers (MetLife Egypt, AXA Egypt, Bupa Egypt, Allianz Egypt, Misr Insurance, Globemed Egypt TPA, Med Net) increasingly include pembrolizumab in higher-tier policies for EDA-registered indications with prior authorisation. For FDA-label indications not yet EDA-registered (the named-patient import lane), payer coverage shifts to case-by-case adjudication and self-pay as the dominant funding source. MSD Egypt's patient-support programme operates case-by-case access support for the registered indications.
Recent regulatory and access news for Keytruda
FDA approved (December 2024) Keytruda plus chemotherapy for first-line endometrial cancer; FDA approved (March 2025) Keytruda plus enfortumab vedotin for first-line locally advanced or metastatic urothelial cancer. The current FDA label and approval letters are at accessdata.fda.gov/scripts/cder/daf. EMA (CHMP) issued multiple Keytruda label expansions in 2024 to 2025 across mirror indications. The EDA News feed at edaegypt.gov.eg/en/news documents periodic registration-approval announcements for Keytruda indications in Egypt as MSD Egypt completes phased indication-by-indication submissions; the gap between FDA approval and EDA indication-specific registration drives the cross-border lane for new indications.
Where Reserve Meds fits in Keytruda cases
Reserve Meds is a US-based concierge coordinator. We do not replace your prescribing physician, we do not replace the EDA, and we do not replace your dispensing pharmacy. For Keytruda specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain logistics with appropriate temperature monitoring into Egypt, plan cycle-by-cycle resupply across longer treatment courses, and assign a single named coordinator through the case. Standard NPP coordination under our cold-chain biologic playbook applies.
Next step
If your Egypt physician has prescribed Keytruda and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.